An observational study in Parkinson Disease, sponsored by University Hospital, Toulouse. Not yet recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by University Hospital, Toulouse · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.
Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is one of 5 that started in 2024, is one of 8 observational ones, and was the 28th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–80 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 40–80
University Hospital, Toulouse · Sites in France
Ages 40–80
University Hospital, Toulouse · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Toulouse · Sites in France, Germany, Spain and 1 more country
Ages 40–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 38 across the 25 interventional studies, 81 across the 8 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
3 of the studies in Parkinson Disease by University Hospital, Toulouse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
| NCT06885541University Hospital, ToulouseDetection of Internal Tremors by Oscillometry in Parkinson's Patient | 2027-05-10 |
| NCT07578272University Hospital, ToulousePrevention of Medical, Social, and Psychosocial Risks Following a Parkinson's Disease Diagnosis: A Pilot Study | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
dBM-dev study is a multicentre low-intervention research study which concerns REM sleep behaviour disorder (RBD) who is the best predictor for neurodegenerative diseases including Parkinson's disease (PD). RBD can only be confirmed by polysomnography, which is a cumbersome procedure. The main objective of this study is to identify a novel, robust dBM for the detection of RBD using smartwatch-based recordings of passive data.The study is conducted step-wise on two subsequent cohorts referred to as the development cohort and the confirmation cohort.
The development cohort comprises 30 patients with RBD and 30 matched controls on sex and age with patients RBD.
The confirmation cohort comprises 30 patients with PD. Following a baseline visit comprising standard clinical evaluation and Parkinson questionnaires, participants will undergo daily-life dBM tracking over a duration of 4 weeks for development cohort and 3 months for confirmation cohort. Additionally, PD patients enrolled in the confirmation cohort will receive a polysomnography which permits to verificate if they have a RBD. The investigation is conducted in four European sites.
1 group of persons with RBD
1 group of persons without RBD
1 group of persons with Parkinson disease
Inclusion Criteria for development cohort:
Group of RBD patients
Group of Healthy matched controls:
Inclusion Criteria for confirmation cohort
Exclusion Criteria for all cohorts:
Inability to consent for study procedures as judged by the investigator. Lacking motivation to participate in study procedures as judged by the investigator.
Lack of social security.
Detection of RBD signs by using the connected smartwach during 4 weeks
Device: connected smartwatch
Detection of RBD signs by using the connected smartwach during 4 weeks
Device: connected smartwatch
Detection of RBD signs by using the connected smartwach during 3 months
Device: connected smartwatch
The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
Incidence of nights in a confirmation cohort in which RBD episodes are indicated by a score (digital biomarker) derived from passive actigraphy and photoplethysmography data captured by a smartwatch
the digital biomarker will be identified from passive actigraphy and photoplethysmography data of a separate development cohort
Time frame: 4 weeks
correlation between a) and b)
1. the incidence of daytime somnolence episodes per week indicated by a score (digital biomarker) derived from passive actigraphy and photoplethysmography data captured by a smartwatch. The digital biomarker will be identified from passive actigraphy and photoplethysmography data of a separate development cohort 2. the score of the Epworth Sleepiness Scale at baseline, measured by the Spearman correlation coefficient, in a confirmation cohort
Time frame: 4 weeks for a) 3 months for b)
Number of camera-based movement assessments acquired by each participant relative to the number of scheduled camera-based movement assessments.
Time frame: 4 weeks (for development cohort) and 3 months (for confirmation cohort)
Number of cognitive tasks completed by each participant relative to the number of scheduled cognitive tasks.
Time frame: 4 weeks (for development cohort) and 3 months (for confirmation cohort)
Start is estimated for Sep 2024; primary completion for Jul 2025, 9 months later.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 9 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →